Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SSR150106 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SSR150106 QD | EXPERIMENTAL | 90 micro grams oral solution once daily (QD) |
| SSR150106 OEQD | EXPERIMENTAL | 90 micro grams oral solution once every other day (OEQD) |
| Placebo | PLACEBO_COMPARATOR | oral solution QD or OEQD |
| Name | Type | Description |
|---|---|---|
| SSR150106 | DRUG | - |
| Placebos | DRUG | - |
Inclusion Criteria: * Either treatment-naïve patients, or those who have discontinued their Rheumatoid Arthritis-directed medication due to intolerability or insufficient efficacy * At least 9 out of 68 tender joints; 6 out of 66 swollen joints; morning stiffness 45 min * C-Reactive Protein \>=1.8 ...
Top 20 of 28 competitors
SSR150106 is an investigational small molecule being studied for the treatment of rheumatoid arthritis. It is designed to reduce inflammation in patients with active rheumatoid arthritis. The drug is currently in clinical development and has not been approved by regulatory authorities.
SSR150106 is a small molecule developed by Sanofi for the treatment of rheumatoid arthritis. Its specific molecular target has not been disclosed in available information. The drug is being investigated for its ability to reduce inflammation in patients with active rheumatoid arthritis.
SSR150106 is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker SNY. The drug is currently in Phase 2 clinical development for the treatment of rheumatoid arthritis.
SSR150106 is in Phase 2 clinical development. It is an investigational drug being studied for the treatment of rheumatoid arthritis. The drug has not been approved by regulatory authorities and remains in clinical trials to evaluate its safety and efficacy.
SSR150106 has been studied in one completed Phase 2 clinical trial, identified as NCT00545454. This randomized, double-blind, placebo-controlled trial enrolled 79 participants with active rheumatoid arthritis and was conducted in Bulgaria, Croatia, Czechia, Romania, Russia, Slovakia, and Ukraine.
SSR150106 is the primary name for this investigational drug developed by Sanofi. No alternative names have been associated with this compound in available information. It is a small molecule being studied for the treatment of rheumatoid arthritis.